10

FEB

26

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

The successful translation of a stem cell-derived product from the laboratory into an approved medicine requires specific scientific, technical, and regulatory understanding. Since this knowledge base is fragmented across websites and publications, the ISSCR has developed a new resource, The Best...

Learn more

Institute for Stem cell Therapy and Exploration of Monogenic diseases

In 2026, advancing research on rare and ultra-rare monogenic diseases requires the mobilization of significant human and technological resources. Within I-Stem, we are all mobilized around this common objective.

+

80

Between scientists and support functions, 80 people currently work at I-Stem.

Teams at the service of ambitious therapeutic objectives

Reasearch
teams

I-Stem brings together within its research teams the expertise and know-how of researchers, teacher-researchers, engineers and technicians. Retinopathies, genodermatoses, Limb-girdle muscular dystrophies, neuromuscular diseases & Myelinated fibers are part of our main scientific themes.

+

Triails
clinics

Clinical trials are a crucial step in the development of treatments for any pathology. I-Stem is the sponsor of several trials and supports others through partnerships.

+

stemCARE
Technology plateform

Excellent research requires state-of-the-art equipment. I-Stem is equipped with technological platforms allowing its research teams to optimize their fundamental, pre-clinical and clinical research projects.

+

News

  • News
  • Publications
Event

19 January 2026

Dr Meryem Baghdadi : Mechano-sensing of the niche regulates stem cell fate decision

Dr. Meryem Baghdadi will present her work at I-Stem on January 22, 2026. : Mechano-sensing of the niche regulates stem cell fate decision.

+
Press release

27 February 2025

The Drug Cell : A new french alliance to redefine cell therapies

The French company “The Drug Cell” (TDC) has just been officially created, marking a decisive step forward for the European cell therapy sector.

+
Press release

16 January 2025

Labeling of the stemCARE Platform by GIS IBiSA

For the 2024 edition of its call for proposals, GIS IBiSA has defined several priority themes, including pluripotent stem cells.
Among the structures specialized in this field, the stemCARE technology platform has been selected for labeling.

+
Discover all the news
Cell biologyHTS.MotoneuronNGS.

14 July 2026

Integrative analysis of drug-gene signatures in human pluripotent stem cells reveals prazosin as a novel SQSTM1 regulator for ALS therapeutics.

The classical paradigm of drug screening often faces significant limitations due to the challenges associated with identifying molecular or cellular read-outs that are relevant to specific genetic diseases. To remedy this, an alternative approach of reverse phenotypic mapping was tested: Compound...

+
Motoneuron

14 July 2026

Rewiring ALS by modulating the autophagy receptor SQSTM1.

Drug screening for genetic disorders is limited by difficulty identifying disease-relevant phenotypes. In this issue, Roussange et al., show that reverse phenotypic mapping could uncover therapeutic gene expression signatures. Using this approach, they identified prazosin, which increases SQSTM1 ...

+
Cell biologyCRISPR.

01 August 2026

Generation of two iPSC lines each carrying a stop codon mutation, c.366T > A (p.Y122X) and c.1657C > T (p.R553X), in the CFTR gene from the parental line PCIi033-A using CRISPR/Cas9.

Cystic fibrosis is a recessive genetic disease due to mutations in the CFTR gene. Approximately 80% of patients carry the CFTR-F508del mutation and may benefit from the triple therapy Kaftrio®. However, patients with other rare mutations that prevent the production of the CFTR protein, such as no...

+
Discover all the publications

I-Stem is a member of the Institute of Biotherapies for Rare Diseases created by the AFM - Telethon